A study of MenABCWY vaccine in healthy adolescents and young adults – if it was safe and produced antibody responses against a germ called Neisseria meningitidis. A Phase 3, Randomized, Active-Controlled, Observer-Blinded Trial to Assess the Safety, Tolerability, and Immunogenicity of MenABCWY in Healthy Participants ≥10 to <26 Years of Age.